148 related articles for article (PubMed ID: 22585604)
1. Expression of von Hippel-Lindau gene product (pVHL) and S100P in cystic neoplasms of the pancreas--with an implication for their roles in tumorigenesis.
Liu H; Shi J; Wang HL; Zhang J; Brown RE; Wilkerson M; Lin F
Ann Clin Lab Sci; 2012; 42(2):109-17. PubMed ID: 22585604
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma-with implication of their roles in early tumorigenesis.
Lin F; Shi J; Liu H; Hull ME; Dupree W; Prichard JW; Brown RE; Zhang J; Wang HL; Schuerch C
Am J Surg Pathol; 2008 Jan; 32(1):78-91. PubMed ID: 18162774
[TBL] [Abstract][Full Text] [Related]
3. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy.
Levy M; Lin F; Xu H; Dhall D; Spaulding BO; Wang HL
Hum Pathol; 2010 Sep; 41(9):1210-9. PubMed ID: 20382408
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of von Hippel-Lindau gene product, maspin, IMP3, and S100P in adenocarcinoma of the gallbladder.
Shi J; Liu H; Wang HL; Prichard JW; Lin F
Hum Pathol; 2013 Apr; 44(4):503-11. PubMed ID: 23079206
[TBL] [Abstract][Full Text] [Related]
5. Use of IMP3, S100P, and pVHL immunopanel to aid in the interpretation of bile duct biopsies with atypical histology or suspicious for malignancy.
Schmidt MT; Himmelfarb EA; Shafi H; Lin F; Xu H; Wang HL
Appl Immunohistochem Mol Morphol; 2012 Oct; 20(5):478-87. PubMed ID: 22495381
[TBL] [Abstract][Full Text] [Related]
6. Cystic neoplasia of the pancreas: pathology and biology.
Adsay NV
J Gastrointest Surg; 2008 Mar; 12(3):401-4. PubMed ID: 17957438
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma.
Lok T; Chen L; Lin F; Wang HL
Hum Pathol; 2014 Feb; 45(2):394-400. PubMed ID: 24439226
[TBL] [Abstract][Full Text] [Related]
8. S100P is an early developmental marker of pancreatic carcinogenesis.
Ohuchida K; Mizumoto K; Egami T; Yamaguchi H; Fujii K; Konomi H; Nagai E; Yamaguchi K; Tsuneyoshi M; Tanaka M
Clin Cancer Res; 2006 Sep; 12(18):5411-6. PubMed ID: 17000674
[TBL] [Abstract][Full Text] [Related]
9. Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas.
Liu H; Shi J; Anandan V; Wang HL; Diehl D; Blansfield J; Gerhard G; Lin F
Arch Pathol Lab Med; 2012 Jun; 136(6):601-9. PubMed ID: 22646265
[TBL] [Abstract][Full Text] [Related]
10. S100P is a novel marker to identify intraductal papillary mucinous neoplasms.
Nakata K; Nagai E; Ohuchida K; Hayashi A; Miyasaka Y; Aishima S; Oda Y; Mizumoto K; Tanaka M; Tsuneyoshi M
Hum Pathol; 2010 Jun; 41(6):824-31. PubMed ID: 20153506
[TBL] [Abstract][Full Text] [Related]
11. Utility of pVHL, maspin, IMP3, S100P and Ki67 in the distinction of autoimmune pancreatitis from pancreatic ductal adenocarcinoma.
Hedegaard Jensen G; Mortensen MB; Klöppel G; Nielsen MFB; Nielsen O; Detlefsen S
Pathol Res Pract; 2020 May; 216(5):152925. PubMed ID: 32273198
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathologic analysis of 92 cases of pancreatic cystic neoplasm].
Ji Y; Zhu XZ; Lou WH; Wang DQ; Jin DY; Zeng MS; Zeng HY
Zhonghua Bing Li Xue Za Zhi; 2007 Mar; 36(3):160-5. PubMed ID: 17535681
[TBL] [Abstract][Full Text] [Related]
13. Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas.
Oda Y; Aishima S; Morimatsu K; Hayashi A; Shindo K; Fujino M; Mizuuchi Y; Hattori M; Tanaka M; Oda Y
Hum Pathol; 2013 Aug; 44(8):1487-98. PubMed ID: 23465281
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Value of S100p, IMP3, Maspin, and pVHL in the Differantial Diagnosis of Pancreatic Ductal Adenocarcinoma and Normal/chronic Pancreatitis in Fine Needle Aspiration Biopsy.
Aksoy-Altinboga A; Baglan T; Umudum H; Ceyhan K
J Cytol; 2018; 35(4):247-251. PubMed ID: 30498299
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of claudin expression in pancreatic cystic tumors.
Lee JH; Kim KS; Kim TJ; Hong SP; Song SY; Chung JB; Park SW
Oncol Rep; 2011 Apr; 25(4):971-8. PubMed ID: 21206985
[TBL] [Abstract][Full Text] [Related]
16. From somatic mutation to early detection: insights from molecular characterization of pancreatic cancer precursor lesions.
Fischer CG; Wood LD
J Pathol; 2018 Dec; 246(4):395-404. PubMed ID: 30105857
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical characteristics and malignant progression of hepatic cystic neoplasms in comparison with pancreatic counterparts.
Matsubara T; Sato Y; Sasaki M; Harada K; Nomoto K; Tsuneyama K; Nakamura K; Gabata T; Matsui O; Nakanuma Y
Hum Pathol; 2012 Dec; 43(12):2177-86. PubMed ID: 22705005
[TBL] [Abstract][Full Text] [Related]
18. Inhibin expression in ovarian-type stroma in mucinous cystic neoplasms of the pancreas.
Yeh MM; Tang LH; Wang S; Robert ME; Zheng W; Jain D
Appl Immunohistochem Mol Morphol; 2004 Jun; 12(2):148-52. PubMed ID: 15354741
[TBL] [Abstract][Full Text] [Related]
19. Current understanding of precursors to pancreatic cancer.
Takaori K
J Hepatobiliary Pancreat Surg; 2007; 14(3):217-23. PubMed ID: 17520195
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic serous cystic neoplasms accompanying other pancreatic tumors.
Kim SW; Song IH; An S; Kim SY; Kim HJ; Song KB; Hwang DW; Lee SS; Byun JH; Seo DW; Kim SC; Yu E; Hong SM
Hum Pathol; 2017 Feb; 60():104-113. PubMed ID: 27816717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
